Assure™ SNP Microarray utilizes a high resolution single nucleotide polymorphism (SNP) analysis for the detection chromosomal alterations. This permits for accurate detection of both large genome copy-number changes and individual genes associated with cancer. Chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS) are especially suitable for Assure™ SNP Microarray analysis because of the high incidence of dosage-related clonal changes that have been proven to have an influence on patient outcomes. Assure™ SNP Microarray detects copy number aberrations seen by karyotype and FISH. Additionally it provides faster, higher-resolution results than standard karyotyping and can help detect clinically significant cryptic aberrations that common FISH panels may not target. Assure™ SNP Microarray quickly identifies copy number changes in hematologic malignancies with a single study.
3-5 cc of blood collected in a green top tube (sodium heparin). It is a New York state requirement that chromosome analysis be performed prior to or concurrently with postnatal microarray analysis. Therefore, send 2 green top tubes with 3-5 cc of blood in each if both chromosome and microarray analyses are requested.
Whole Blood Green top (sodium heparin) tubes
- Assure™ SNP microarray includes 2.67 million markers for copy number (CN) analysis, approximately 750,000 SNP probes, and 1.9 million non-polymorphic probes for comprehensive whole-genome coverage.
- 100% Sanger cancer gene coverage
- 100% ISCA constitutional gene coverage
- 12,000 OMIM® genes
- 36,000 RefSeq genes
- SNP analysis can detect copy neutral changes including uniparental disomy (UPD) and areas of homozygosity suggestive of consanguinity. Abnormal results are confirmed with Fluorescence In Situ Hybridization (FISH analysis).
Room temperature (DO NOT refrigerate, freeze, or centrifuge).
Causes for Rejection
Frozen specimen, inappropriate container